Iol Chemicals & Pharmaceuticals Ltd. · NSE:IOLCP
Iol Chemicals & Pharmaceuticals — Investor Presentation (April 2022)
15 slides from Iol Chemicals & Pharmaceuticals's investor presentation, April 2022
Slide 1: Investor Discussion
Investor Discussion Pharma Industry IOL Chemicals And Pharmaceuticals Limited April 2022
Slide 2: World Pharmaceutical Market
World Pharmaceutical Market Global Industry Overview Source: European Federation of Pharmaceutical Industries and Associations ➢ The growth of the genomics market is being propelled by the increasing prevalence of chronic diseases, plummeting DNA sequencing costs, and Global growing funding for geno
Slide 3: Structure Of Pharmaceuticals Sector
Structure Of Pharmaceuticals Sector Pharmaceutical Industry Structure Bulk Drugs Contract Research and Finished Dosage Formulation Biopharmaceuticals (Active Pharma Ingredients Manufacturing Services (FDF) and Biosimilars and Intermediates) (CRAMS) Active Pharma Ingredients: Biopharmaceuticals FDF i
Slide 4: Indian Pharma Industry
Indian Pharma Industry • Globally, India ranks 3rd in terms of pharmaceutical production by volume and 14th by value. Source: IBEF ( Indian Brand Equity Foundation) • India is the world's largest supplier of generic medications, accounting for 20 % of the worldwide supply by volume and supplying abo
Slide 5: Market categorization of API companies
Market categorization of API companies • These are aggressive API companies who explore early launch opportunities 1 First-to-file Players by exploring para-4 options. • Conflict between in-house consumption versus external customer offering is the key. Example – TAPI, MSN, Cadilla, Dr. Reddy’s, Sun
Slide 6: API industry – Key trends in the last few quarters
API industry – Key trends in the last few quarters Key themes Trends Technology • Increased investments in new technologies Ex. Divi’s – Micro-reactors, HPAPI – several cos, DRL – continuous manufacturing 1 play • Strategic partnerships to acquire technologies Ex. Almelo – Sitagliptin technology • C
Slide 7: Company mapping – Shift towards Value & Complex products in last Decade
Company mapping – Shift towards Value & Complex products in last Decade 2012 2022 DRL Divi’s Divi’s Solara Aarti1 High Laurus High Piramal Piramal IOL Product value DRL Product value Shasun Glenmark Aurobindo Aarti2 Glenmark Aarti Aurobindo Laurus Low Low IOL Low High Low High Product volume Product
Slide 8: About IOL Chemicals and Pharmaceuticals Limited
About IOL Chemicals and Pharmaceuticals Limited Incorporated in 1986, IOLCP is one of the leading APls / bulk drugs company and is a significant player in the field of specialty chemicals with world class facilities R&D Centre is approved by Department of Scientific and Industrial Research (DSIR) an
Slide 9: Key Highlights
Key Highlights Team size of 2,300+ Largest producer of Largest producer of Ethyl 2nd Largest producer of Over 20 products are employees Ibuprofen and the only Acetate at Single Location Iso Butyl Benzene (IBB) commercialised with 8 company worldwide being in India with ~30% Global share products in
Slide 10: Professional Management Team
Professional Management Team Mr. Varinder is an industrialist and has wide and rich Mr. Vikas is academically equipped with the experience of more than 35 years in the chemical & knowledge and possesses organizational capacity. He fertilizer industry and along with a comprehensive has worked in stra
Slide 11: Business Verticals
Business Verticals API - Commercialized API Under Validation Ibuprofen Paracetamol Metformin HCL API Quetiapine Fumarate Clopidogrel Bisulphate (Form II) Allopurinol Pantoprazole Sodium Irbesartan Fenofibrate (Micronised) Valsartan Gabapentin Vildagliptin Product Lamotrigine Segmentation API Pipelin
Slide 12: Regulatory Approvals
Regulatory Approvals 10 v v v v v v v Levetiracetam Anti-Epileptic 102767-28-2 250 Filed - - Filed - v v l l Ibuprofen NSAID 15687-27-1 1000 i Ibuprofen v . Lysinate NSAID 57469-76-8 175 - - - - - - I Ibuprofen c=. . . 7 . . . v . Sodium NSAID 31121-93-4 450 I Dex-Ibuprofen NSAID 51146-56-6 19 kg -
Slide 13: Financial Summary – Statement of Profit & Loss
Financial Summary – Statement of Profit & Loss P&L (INR Crs) FY17 FY18 FY19 FY20 FY21 Q3FY22 Q2FY21 Q3FY21 9M FY22 9M FY21 Revenues 710.6 983.3 1,685.3 1,894.5 1,967.0 555.1 537.9 513.0 1611.5 1506.6 Other Income 1.3 6.3 10.4 16.0 24.3 8.9 10.5 7.8 25.1 18.1 Total Income 711.9 989.6 1,695.7 1,910.5
Slide 14: 5 years Financial Performance - Annually
5 years Financial Performance - Annually Revenues & Margins* – Annual Margin* Expansion – Over the Years 50% Gross % 2,000 1,910 1,991 50% 45% 45% 1,800 1,696 45% 12% 45% 44% 40% 1,600 40% EBITDA % 38% 35% 33% 31% 1,400 33% 31% 31% 35% 30% 1,200 30% 30% 16% 25% PAT % 990 22% 25% 22% 1,000 25% 19% 80
Slide 15: Thank You!
IOL Chemicals and Pharmaceuticals — Investor Presentation (April 2022) on 6ix